310 related articles for article (PubMed ID: 20706990)
1. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
Jelkmann W
Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars: it's not as simple as cost alone.
Roger SD; Goldsmith D
J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
[TBL] [Abstract][Full Text] [Related]
3. Assessing the bioequivalence of biosimilars The Retacrit case.
Schellekens H
Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
[TBL] [Abstract][Full Text] [Related]
4. Follow-on biologics: challenges of the "next generation".
Schellekens H
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
[TBL] [Abstract][Full Text] [Related]
5. Biosimilars: current status and future directions.
Roger SD
Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
[TBL] [Abstract][Full Text] [Related]
6. Biosimilar medicines--new challenges for a new class of medicine.
Fox A
J Biopharm Stat; 2010 Jan; 20(1):3-9. PubMed ID: 20077245
[TBL] [Abstract][Full Text] [Related]
7. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
8. Non-clinical safety studies on biosimilar recombinant human erythropoietin.
Parnham MJ; Schindler-Horvat J; Kozlović M
Basic Clin Pharmacol Toxicol; 2007 Feb; 100(2):73-83. PubMed ID: 17244255
[TBL] [Abstract][Full Text] [Related]
9. [Biosimilars or follow-on biologics in dermatology].
Puig L
Actas Dermosifiliogr; 2010; 101(1):4-6. PubMed ID: 20109387
[No Abstract] [Full Text] [Related]
10. Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments.
Jelkmann W
Expert Opin Biol Ther; 2012 May; 12(5):581-92. PubMed ID: 22471247
[TBL] [Abstract][Full Text] [Related]
11. [Biosimilar products--cheaper version of biological drugs. New possibilities within several therapeutic fields].
Mellstedt H
Lakartidningen; 2009 Jun 3-9; 106(23):1563-6. PubMed ID: 19583014
[No Abstract] [Full Text] [Related]
12. Basic facts about biosimilars.
Nowicki M
Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars: pharmacovigilance and risk management.
Zuñiga L; Calvo B
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
[TBL] [Abstract][Full Text] [Related]
14. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
15. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars--science, status, and strategic perspective.
Kresse GB
Eur J Pharm Biopharm; 2009 Aug; 72(3):479-86. PubMed ID: 19286455
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins.
Combe C; Tredree RL; Schellekens H
Pharmacotherapy; 2005 Jul; 25(7):954-62. PubMed ID: 16006274
[TBL] [Abstract][Full Text] [Related]
19. Epoetin biosimilars in Europe: five years on.
Mikhail A; Farouk M
Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
[TBL] [Abstract][Full Text] [Related]
20. The challenge of follow-on biologics for treatment of multiple sclerosis.
Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
